Kremyanskaya Highlights the Benefits of BET Inhibitors in Myelofibrosis

0 Visualizações· 07/03/23
OncLive® On Air
OncLive® On Air
0 Assinantes
0
Dentro

Dr Kremyanskaya discusses the results from cohort 1 of the MANIFEST trial in treatment-naïve myelofibrosis, differentiating features of pelabresib and recently approved JAK inhibitors, and next steps for the investigation of BET inhibitors in this population.

Mostre mais

 0 Comentários sort   Ordenar por


A seguir